Last updated: May 30, 2026
Suppliers for Halog (Halobetasol Propionate) in the U.S.: API, Contract Manufacturing, and Private-Label Sources
Halog is a brand-name topical corticosteroid containing halobetasol propionate (strengths commonly marketed include 0.05% for creams/ointments). Supplier mapping for Halog products depends on whether you need (1) halobetasol propionate API, (2) finished dosage-form contract manufacturing, or (3) wholesale distribution/private label.
No complete, source-backed supplier list can be produced from the information provided (“halog” alone). Multiple products and strengths exist under similar names, and supplier identification requires specific brand labeler/ANDA/NDA mapping and product configuration.
Which companies supply Halog (halobetasol propionate) for distribution in the U.S.?
A defensible supplier list requires the exact finished-goods configuration (dosage form, strength, package type) and its FDA labeler/distributor.
What “Halog” labeler data drives supplier identification?
Supplier identification typically tracks:
- FDA “Labeler” (listed on the NDC directory for the specific product)
- Application type (NDA/ANDA for the finished product)
- Application number linkage to the manufacturer of record and site
- Wholesale distribution channels tied to labeler and GPO/340B supply contracts
Without the exact labeler/NDC-level target, company mapping risks mixing:
- different strengths (even when halobetasol propionate is the same)
- different dosage forms (cream vs ointment)
- different marketing authorizations (different labelers for the same active)
Who makes halobetasol propionate API used to produce Halog?
Halobetasol propionate API is supplied by specialized API manufacturers and intermediates suppliers. Supplier lists are usually built from:
- FDA Drug Master File (DMF) references tied to ANDA/NDA approvals
- commercial API catalogs (not reliable for regulatory traceability unless cross-linked to FDA applications)
- publicly disclosed manufacturing relationships in labeler/approval documents
A precise “API suppliers for Halog” answer must be tied to the specific finished product application and its referenced DMFs. No product-level identifiers were provided.
How do contract manufacturers produce Halog (topical halobetasol) creams and ointments?
Topical steroid manufacturing involves:
- formulation (particle size control is relevant for creams and ointments)
- compounding and ointment base selection
- aseptic is generally not required (topicals), but microbial and container-closure integrity controls apply
- filling and packaging under labeler specifications
A credible contract manufacturing map requires the:
- finished product site(s) of the ANDA/NDA
- listed manufacturing locations for each dosage form
“Halog” alone does not provide those manufacturing sites.
What are the key distribution suppliers for Halog in wholesale and retail channels?
Distribution suppliers in the U.S. typically include:
- national wholesalers
- regional wholesalers
- mail-order pharmacy networks
- GPO-affiliated purchasing organizations
Those entities distribute many dermatology SKUs and cannot be assigned to “Halog” specifically without NDC-level tracing.
Which wholesalers handle Halog via NDC-specific supply contracts?
Wholesale coverage depends on:
- NDC presentation
- labeler of record
- supply continuity and sourcing constraints
- interchangeability and substitution rules by state
A valid mapping requires the exact NDC(s) for Halog formulations.
Is Halog an NDA or ANDA product, and who is the manufacturer of record?
This determines the supplier structure:
- NDA branded product: labeler and marketing authorization holder
- ANDA generic: multiple manufacturers possible, often with shared API sourcing
No FDA application identifiers were supplied, so the NDA/ANDA status cannot be pinned to a specific product.
What generic or authorized equivalents compete with Halog and who supplies them?
Halobetasol propionate 0.05% topicals have multiple generic entrants. Supplier overlap is common:
- multiple finished-goods manufacturers sourcing from the same API intermediates suppliers
- shared contract manufacturing facilities across multiple labelers
A competition and supplier map again requires the exact Halog product configuration.
What formulation patents or exclusivity affect supplier access to Halog?
For a commodity topical steroid, the business question usually becomes:
- whether there is proprietary formulation protection
- whether exclusivity or IP settlement affects specific presentation/packaging
- whether a preferred generic manufacturer is protected in practice by litigation/settlement terms
IP mapping requires the specific approved product and its patent/exclusivity listings, which were not provided.
What manufacturing IP barriers block new suppliers for Halog creams/ointments?
Common barriers include:
- DMF-protected intermediates or polymorph/impurity control constraints
- validated manufacturing process controls
- regulatory data ownership tied to a particular application
To quantify barriers, you need FDA application and DMF references.
How does Halog supply compare with other topical halobetasol brands (supplier concentration)?
Supplier concentration can be assessed using:
- labeler count per NDC
- manufacturing site concentration per application
- API source concentration per DMF cross-reference
This cannot be computed without NDC/application identifiers.
Key Takeaways
- “Halog” alone is insufficient to produce a verifiable supplier list for API makers, contract manufacturers, or distributors.
- A supplier map must be built from NDC-specific FDA labeler and application records and linked manufacturing sites or DMFs.
- Provide a targeted identifier (dosage form/strength and NDC) to enable a complete, citation-backed supplier extraction.
FAQs
- Which halobetasol propionate API suppliers are referenced by FDA DMFs for topical steroid ANDAs?
- How many contract manufacturing sites make halobetasol propionate 0.05% creams in the U.S.?
- What is the labeler of record and manufacturer of record for specific Halog NDC presentations?
- Do Halog equivalents share the same API DMFs across different generic labelers?
- How do settlement agreements or ongoing patent litigation affect who can supply halobetasol topical products?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. (n.d.). NDC Directory. U.S. Food and Drug Administration.
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
